Abstract
Background As a member of the exon junction complex (EJC), RNA-binding motif protein 8A (RBM8A) plays a crucial role in the maintenance of mRNA and multiple activities of an organism. Immunotherapy has been proven to be a staple type of cancer treatment. However, the role of RBM8A and immunity across cancer types is unclear. Objective This study aims to visualize the expression, prognosis, mutations, and coexpressed gene results of RBM8A across cancer types and to explore the link between RBM8A expression and immunity. Methods In this study, data were collected from multiple online databases. We analyzed the data using the HPA, UALCAN Database, COSMIC, cBioPortal, Cancer Regulome tools, Kaplan–Meier Plotter, and TIMER website. Results For the expression of RBM8A in normal tissues, higher expression of RBM8A was observed in immune-related cells than in nonimmune organs. The expression level of RBM8A was related to tumor type. Missense mutations in RBM8A were found in most tumors and affected the prognosis of carcinomas with coexpressed genes. RBM8A was strongly associated with immune-infiltrating cells and immune checkpoint inhibitors, especially in LIHC. Conclusions RBM8A is a gene worth exploring and may be a unique immune target in the future.
Highlights
Cancer is an incurable disease and has become a major global cause of morbidity and mortality. e reported figures for the 2018 Global Cancer Estimate have indicated 18.1 million new cancer cases and 9.6 million deaths from cancer in 2018 [1]
The discovery and clinical application of checkpoint inhibitors have greatly accelerated the process of immunotherapy. e cytotoxic T lymphocyte antigen 4 (CTLA4) or programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis is approved for use in a variety of cancer types [2]
As shown in the results of the Consensus dataset and Human Protein Atlas (HPA) dataset in Figure 1, compared with other normal tissues, we observed higher expression of RNA-binding motif protein 8A (RBM8A) in B cells, T cells, NK cells, dendritic cells, granulocytes, and monocytes. erefore, we believe that RBM8A is more highly expressed in immune-related cells than in nonimmune organs
Summary
Cancer is an incurable disease and has become a major global cause of morbidity and mortality. e reported figures for the 2018 Global Cancer Estimate have indicated 18.1 million new cancer cases and 9.6 million deaths from cancer in 2018 [1]. It has been found that immune checkpoint inhibitors are not effective for all cancer populations, and some may even lead to serious immune-related adverse events in patients [3, 4]. Immunotherapy has been proven to be a staple type of cancer treatment. The role of RBM8A and immunity across cancer types is unclear. Is study aims to visualize the expression, prognosis, mutations, and coexpressed gene results of RBM8A across cancer types and to explore the link between RBM8A expression and immunity. RBM8A was strongly associated with immune-infiltrating cells and immune checkpoint inhibitors, especially in LIHC. RBM8A is a gene worth exploring and may be a unique immune target in the future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
